Biomarker-Defined Metastatic Solid Tumors

Too many loved ones live with uncertainty.
Let’s find answers.

Precision medicine is transforming how we treat cancer. We know that a patient’s response to treatment can depend on the genetic makeup of their cancer and are applying a precision medicine approach to develop new treatments for a number of highly prevalent, biomarker-defined metastatic cancers. Our ambition is for patients with cancer to lead longer, better lives.

Let’s go vertical

We are collaborating with BeiGene to take a vertical inhibition approach to the MAPK pathway. A study combining our MEK inhibitor with BeiGene’s RAF dimer inhibitor represents a unique opportunity to treat patients with MAPK-driven cancers, particularly those with RAS mutations, where rational targeted therapies are urgently needed for patients. We believe that through a potent and optimized vertical inhibition combination therapy approach, we may be able to address several biomarker-defined patient subsets within the broader MAPK-mutated solid tumor space.

A Phase 1b/2 clinical trial is ongoing to evaluate mirdametinib in combination with lifirafenib, BeiGene’s RAF dimer inhibitor in patients with advanced or refractory solid tumors that harbor RAS mutations, RAF mutations and other MAPK pathway.
A Phase 1b/2a study is evaluating the safety and tolerability and anti-tumor efficacy of mirdametinib in combination with fulvestrant, a selective estrogen receptor degrader (SERD), in postmenopausal patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) harboring NF1 loss-of-function or other alterations of the MAPK pathway.
A Phase 1b/2a study is evaluating the safety and tolerability and anti-tumor efficacy of mirdametinib as a monotherapy in adult patients with advanced solid cancers harboring MEK1 or MEK2 mutations.
A Phase 1 clinical trial is ongoing to evaluate BGB-3245, a novel oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 B-RAF mutations, non-V600 B-RAF mutations and RAF fusions in patients with advanced or refractory solid tumors harboring specific B-RAF driver mutations and fusions.